Navigation Links
ADVENTRX Provides Update on Strategic Transaction Process
Date:2/10/2009

r partnering transaction or raise sufficient capital to fund the projects necessary to meet its goals, including funding the continued development and commercialization of ANX-530 or ANX-514; the risk that the Company's recent cost-containment measures, as well as any future workforce reductions and/or reductions/delays in spending, will further impact the Company's development and commercialization plans, including its ability to achieve on time its previously stated goals; the risk that the departure of the Company's former Chief Executive Officer and President and Executive Vice President and Chief Financial Officer and/or ADVENTRX's leadership by a committee of executive officers will negatively impact ADVENTRX's ability to execute its business plan or to maintain effective disclosure controls and procedures or internal control over financial reporting; the risk the FDA will determine that ANX-530 and Navelbine are not bioequivalent, including as a result of performing pharmacokinetic equivalence analysis based a patient population other than the population on which ADVENTRX based its analysis; the risk that the bioequivalence study of ANX-514 does not demonstrate pharmacokinetic equivalence or bioequivalence to Taxotere; the risk of investigator bias in reporting adverse events as a result of the open-label nature of the ANX-530 bioequivalence study, including bias that increased the reporting of adverse events associated with Navelbine and/or that decreased the reporting of adverse events associated with ANX-530; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX- 514, including validating commercial manufacturers and suppliers and the potential for automatic injunctions regarding FDA approval of ANX-514; the potential for regulatory authorities to require additional preclinical work or other clinical requirements to support regulatory filings, including prior to the submission or
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. ADVENTRX Announces Consolidation of Clinical and Management Positions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , A major pan-European survey ... delivery of care has revealed changing trends in many ... the provision of healthcare services across the continent. The ... European Gastroenterology (UEG), have been announced today and led ... the burden of GI disorders across Europe ...
(Date:10/20/2014)... Virginia (PRWEB) October 20, 2014 ... NDA Partners LLC, announced today that Ellen Teplitzky, ... legal support for the pharmaceutical industry, has joined ... manager of its legal services practice. NDA ... and expert witness and testimony, to top law ...
(Date:10/19/2014)... , Oct. 19, 2014 NextCODE Health, which ... whole genome in real time, today announced the launch of ... NextCODE Exchange , at the American Society of Human Genetics ... To learn more, sign up and apply for free beta ... unique features and benefits can be viewed here . ...
(Date:10/19/2014)... October 19, 2014 The report "Chocolate, ... Share, Trade, Prices, Geography Trend and Forecast (2011 - ... category, and geography and studies the major market drivers, ... America, Europe, and Asia. , The global chocolate market ... $98.3 billion in 2016 at an estimated CAGR of ...
Breaking Biology Technology:Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5NDA Partners Appoints Ellen Teplitzky, JD as Director of its Legal Services Practice 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 2The NextCODE Exchange: The first global, real-time system for sharing full-resolution genomic data 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 2Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 3Chocolate Market Projected To Reach $98.3 Billion by 2016 - New Report by MarketsandMarkets 4
... 2012 AMRI (NASDAQ: AMRI ) announced ... functions. (Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO ) ... teams are being combined into one functional sales organization, ... promoted to Vice President, Business Development, North America. This ...
... 23, 2012   Covington & Burling represented AstraZeneca in ... the agreement, AstraZeneca will pay $32 per share ... (Logo: http://photos.prnewswire.com/prnh/20120423/CL92331LOGO  ) ... business with a primary focus on the discovery, ...
... Ahram Biosystems, Inc., a leading innovator of new life ... the economy model of its innovative portable PCR system. The ... PCR amplification with high speed and sensitivity in a fully ... provides three " Standard Fast" speed levels delivering 30-cycle ...
Cached Biology Technology:AMRI Strengthens Business Development and Marketing Groups 2AMRI Strengthens Business Development and Marketing Groups 3Covington Advises AstraZeneca in $1.26 Billion Acquisition of Ardea Biosciences 2Ahram Biosystems Announces Launch of the New Economy Model F1-12 of Its Palm PCR Series 2
(Date:10/15/2014)... ability to assess the pandemic risk from strains of ... must not allow ourselves to become complacent that the ... consortium of scientists. , Influenza pandemics arise when a ... to develop widespread immunity – spreads in the human ... past 100 years, the worst of which – the ...
(Date:10/15/2014)... 15, 2014 NXT-ID, Inc. (NASDAQ: NXTD ... on the growing mobile commerce market releases photos and video of ... on Monday October 13 th . Gino ... and angel investor Mr. Chad A. Verdi rang ... NXT-ID thanked his investors and employees "for their work and dedication ...
(Date:10/14/2014)... Ohio (Oct. 14, 2014)—It,s been millions of years since ... a team led by Ohio University scientists is breathing ... model airflow through dinosaur snouts. The research has important ... only breathe but to enhance the sense of smell ... ,nosy, animals," said Ohio University doctoral student Jason Bourke, ...
Breaking Biology News(10 mins):Scientists 'must not become complacent' when assessing pandemic threat from flu viruses 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 2Photo Release: NXT-ID Inc. Rings Opening Bell of the NASDAQ Stock Market October 13th 3Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3
... The American Association for Cancer Research, the world,s oldest ... M.D., on his nomination by President Barack Obama to ... Institute (NCI). "Dr. Varmus will bring to the ... as the foundation for understanding healthy function as well ...
... the venue for the 3rd Baltic Congress of Osteoporosis ... congress, to be held in English, is jointly organized ... Lithuanian Osteoporosis Foundation, Lithuanian Association of Metabolic Bone Diseases ... the most disabling conditions of older adults and elderly. ...
... international team of scientists have discovered that climate change played ... the late quaternary era, 50,000 years ago. Their study, published ... hotly debated topic by using global data modelling to build ... present (BP) 65% of mammal species weighing over 44kg went ...
Cached Biology News:AACR nomination of Harold E. Varmus, M.D., as director of the NCI 2New study reveals link between 'climate footprints' and mass mammal 2
NuParaffin Kit Application: Flow Cytometry Reactivity: Human...
Immunofixation Gel Kit, requires IF100 Reactivity: Human Applications: Immunofixation ...
...
...
Biology Products: